Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZASITE vs COMBOGESIC IV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.
Treatment of bacterial conjunctivitis caused by susceptible organisms
Management of mild to moderate pain,Reduction of fever (acetaminophen component),Off-label: Acute pain relief in various settings
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Paracetamol: 1.5-3 hours; tramadol: 6 hours (active metabolite M1: 7-9 hours). Clinical context: Extended half-life in hepatic impairment (cirrhosis) and elderly; requires dose adjustment.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Acetaminophen: Hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor) to reactive metabolite NAPQI. Ibuprofen: Hepatic via CYP2C9 and CYP2C8 to inactive metabolites.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal: 90% as glucuronide conjugates and unchanged drug for paracetamol; biliary: 10% for paracetamol. For tramadol: renal 90% (unchanged and metabolites), fecal 10%.
~50-60% bound to plasma proteins (primarily albumin).
Paracetamol: 10-25% bound to albumin; tramadol: 20% bound to albumin; active metabolite M1: negligible binding.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
Paracetamol: 0.9 L/kg; tramadol: 2.7 L/kg (wide distribution into tissues). Clinical meaning: High Vd for tramadol indicates extensive tissue distribution.
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
IV: 100% for both components. Oral: Paracetamol 85-90%; tramadol 75% (first-pass metabolism). Not applicable for IM/SC routes.
No dosage adjustment required for ophthalmic use.
e GFR 30-50 m L/min: administer every 6 hours; e GFR <30 m L/min: not recommended; dialysis: contraindicated.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Safety and efficacy in pediatric patients have not been established; limited data available.
Children >12 years and ≥50 kg: same as adult dose; <12 years or <50 kg: not recommended due to codeine; use alternative analgesic.
No specific dosage adjustment recommended; use same dosing as for adults.
Initiate at lowest effective dose; monitor for respiratory depression and hypotension; consider reduced dose or extended interval due to age-related clearance decline.
None
Risk of severe hepatic injury with acetaminophen; do not exceed maximum daily dose (4 g/day).
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Hepatotoxicity (acetaminophen overdose), GI bleeding/ulceration (ibuprofen), renal impairment, cardiovascular thrombotic events (ibuprofen), anaphylactic reactions, masking of infection signs.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Hypersensitivity to any component, active GI bleeding, severe hepatic impairment, severe renal impairment (Cr Cl <30 m L/min), history of asthma/urticaria with NSAIDs, perioperative pain in CABG surgery.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
Concurrent food intake does not affect IV administration. However, patients should avoid alcohol consumption due to increased risk of hepatotoxicity from paracetamol and gastrointestinal bleeding from ibuprofen. No other specific food interactions are known.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use. Second trimester: NSAIDs associated with oligohydramnios and fetal renal effects; acetaminophen safe at therapeutic doses. Third trimester: NSAIDs contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment; acetaminophen preferred.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
Acetaminophen: Low transfer into breast milk, M/P ratio 0.91-1.42; considered compatible with breastfeeding. Ibuprofen (if applicable, assuming NSAID component): M/P ratio 0.01-0.06, very low levels; considered compatible. Avoid NSAIDs if infant has thrombocytopenia or renal impairment. Monitor infant for rash, drowsiness, or gastrointestinal effects.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Acetaminophen: No dose adjustment needed; use lowest effective dose. NSAID component: Avoid in third trimester; if necessary in earlier trimesters, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased plasma volume, enhanced clearance) may require higher acetaminophen dosing but not standardly adjusted; monitor effect.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
COMBOGESIC IV is a fixed-dose combination of paracetamol (acetaminophen) 1000 mg and ibuprofen 300 mg per 100 m L solution. Administer only as a single intravenous infusion over 15 minutes. Do not administer if the solution contains particulates or is discolored. Avoid use in patients with severe hepatic impairment (Child-Pugh C), severe renal impairment (e GFR <30 m L/min/1.73m²), active peptic ulcer disease, or history of aspirin allergy. Monitor for signs of hepatotoxicity (paracetamol) and renal toxicity (ibuprofen). Contraindicated in patients with severe heart failure (NYHA III/IV) or preoperative CABG surgery. Use lowest effective dose for shortest duration. Not recommended for patients <18 years due to lack of safety data. Contains ibuprofen; risk of serious GI adverse events including bleeding, ulceration, and perforation, especially in elderly. Do not exceed 4 doses (4000 mg paracetamol/1200 mg ibuprofen) per day. Concomitant use of other NSAIDs or paracetamol-containing products is contraindicated.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
This medication is given intravenously and is not for self-administration.,Inform your healthcare provider if you have a history of liver or kidney disease, stomach ulcers, bleeding disorders, heart disease, high blood pressure, or asthma.,Avoid taking any additional acetaminophen (paracetamol) or NSAIDs (e.g., ibuprofen, naproxen) while receiving this medication.,Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing), stomach pain, black or bloody stools, vomiting blood, unusual bruising or bleeding, yellowing of skin or eyes, dark urine, or severe fatigue.,Do not consume alcohol while being treated with this medication; alcohol increases the risk of liver damage and stomach bleeding.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery if affected.,Tell your doctor about all medications you are taking, including prescription, over-the-counter, and herbal products, especially blood thinners (warfarin, aspirin), diuretics, lithium, methotrexate, and ACE inhibitors.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZASITE vs COMBOGESIC IV, answered by our medical review team.
AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. COMBOGESIC IV is a Analgesic Combination (Opioid + Non-Opioid) that works by Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZASITE and COMBOGESIC IV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. The standard adult dose of COMBOGESIC IV is: 1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZASITE and COMBOGESIC IV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. COMBOGESIC IV is classified as Category C. First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.